TEST:

BostonGene Tumor Portrait™ Test

P=NA | N=NA | "The event, held from March 22-27 at the Boston Convention and Exhibition Center in Boston, MA....A recent pilot study uncovered associations between bacterial profiles, the tumor microenvironment (TME), and histology in metastatic castration-resistance prostate cancer (mCRPC). Using BostonGene’s machine learning-based tools, RNA sequencing data were analyzed to characterize each sample’s microbiota and TME. Distinct bacterial patterns were present across prostate cancer subtypes and TME classifications, with strong correlations observed among the microbiomes of metastatic sites."

"BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced its participation in the 22nd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2025) from March 6–8, 2025, in Kobe, Japan. This premier conference is dedicated to advancing precision oncology and fostering collaboration among global oncology experts...Unraveling sarcomatoid features in clear cell renal cell carcinoma with RNA-seq: This presentation will showcasethe value of predictive modeling in developing targeted therapy to treat clear cell renal carcinoma, emphasizing BostonGene’s Tumor Portrait^TM test in identifying unique and targetable clinical characteristics in cancer. "

Conclusions The presented liquid biopsy-based approach demonstrates the feasibility of identifying malignant cell fraction, BCR repertoires, clinically significant mutations, and immune and tissue specific processes from cfRNA. This study also suggests that the cfRNA platform may support longitudinal monitoring of CLL progression and relapse, as well the development of MRD tests with future validation.

Over half of cases with luminal molecular phenotype demonstrate immune-enriched TME, suggesting a potentially significant role for immunotherapy in these patients and expanded efforts in this arena. Using the BG Tumor PortraitTM assay, low TMB and MSS was present in the majority of IBC samples evaluated in spite of numerous studies showing common DNA repair mutations. HER2 expressing cases demonstrated a predominantly immune-desert phenotype and further study of the clinical relevance and validation of this is warranted.

"Fujita Health University and BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, announced today that the Fujita Health University Haneda Clinic will now offer genomic profile testing for cancer patients utilizing the BostonGene Tumor Portrait test."

Ethics Approval The use of clinical samples was conducted in accordance with the Declaration of Helsinki and has been granted exemption from ethics approval by the Biomedical Research Alliance of New York (BRANY) Institutional Review Board (BRANY study #22-12-938-853).Download figure Open in new tab Download powerpoint Abstract 183 Figure 1 Oncoplot showing top ten actionable biomarkers per sample in the whole cohort (left). Bubble-plot showing frequency of diagnostic fusions & TME subtypes (right)View this table:View inline View popup Download powerpoint Abstract 183 Table 1 Clinicopathologic data of included patients (N=356) and actionable finidings

Angiosarcoma tumor profiling also uncovered potentially targetable and clinically relevant alterations in these tumors, which may expand treatment options. Ethics Approval The use of clinical samples was conducted in accordance with the Declaration of Helsinki and has been granted exemption from ethics approval by the Biomedical Research Alliance of New York (BRANY) Institutional Review Board (BRANY study #22-12-938-853).View this table:View inline View popup Download powerpoint Abstract 161 Table 1 Genomic and transcriptomic alterations identified in the analyzed samples of angiosarcoma patients (N = 39)View this table:View inline View popup Download powerpoint Abstract 161 Table 2 Characteristics of patients with available information about prior ICI therapy

P=N/A; Not yet recruiting --> Recruiting

"BostonGene...announced that eight abstracts were selected for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, which will be held from April 5 - 10, at the San Diego Convention Center in San Diego, CA. BostonGene will exhibit at booth #847....This study shows the feasibility and utility of comprehensive molecular profiling to match patients to WES-informed treatments within a clinically relevant time frame. The high rate of additional actionable findings identified by BostonGene’s analytical platform suggest comprehensive testing may offer benefit over traditional targeted panels in solid tumor patients."

"BostonGene...today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory. ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial. ComboMATCH aims to overcome drug resistance to single-drug therapies by developing targeted drug combinations. NCI is a part of the National Institutes of Health....A unique initiative to test new combinations of cancer drugs guided by tumor biology, ComboMATCH aims to pair patients with locally advanced or advanced solid tumors with a therapy that has the potential to manage their cancer. The study will also assist physicians in devising more effective treatment strategies."

Clinically significant findings, such as ABC COO (n = 16), TP53 loss (n = 13), DHITsig+ (n = 6), and CARD11 mutations associated with ibrutinib resistance (n = 3), were identified in 33 samples... Our results show the clinical utility and acceptable TAT of using a comprehensive WES and RNA-seq assay on a cohort of lymphoma patients. The produced BostonGene Tumor PortraitTM test reports included findings on significant alterations, LymphGen and LME subtypes, COOs, and potential clinical trial matches. These robust findings, coupled with the rapid TAT, demonstrate the feasibility of using integrated WES and RNA-seq to guide clinical decision-making in lymphoma patients.

P=N/A, N=400, Not yet recruiting, BostonGene